



Max Planck Institute for
Biophysical Chemistry



UNIVERSITÄTSMEDIZIN : UMG
GÖTTINGEN



Dr. Carmen Rotte
Head of public relations
Am Faßberg 11, 37077 Göttingen, Germany
phone: +49 551 201-1304
email: carmen.rotte@mpibpc.mpg.de

Press Release

Dezember 19, 2017

Experimental drug interferes with different mechanisms associated to Alzheimer's disease

The chemical compound anle138b eases cognitive deficits and normalizes gene expression in a mouse model of Alzheimer's disease. Furthermore, the drug seems to close harmful openings in the membrane of nerve cells. An international collaboration reports these findings in the journal *EMBO Molecular Medicine*. The scientists suggest that anle138b should be validated in clinical trials for its potential to treat Alzheimer's and possibly other neurodegenerative diseases. The study involved institutions from Europe and the US including the German Center for Neurodegenerative Diseases (DZNE), the University Medical Center Göttingen (UMG), the Max Planck Institute for Biophysical Chemistry (MPI-BPC), the Center for Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB), Göttingen, the Technische Universität Braunschweig, and the University of California San Diego (UC San Diego).


Alzheimer's is a devastating neurodegenerative condition ultimately leading to dementia. An effective treatment does not yet exist. The disease is associated with the aberrant aggregation of small proteins called A β -peptides that accumulate in the brain and appear to harm neurons. However, the molecular events that lead to neurodegeneration are not entirely resolved.

"According to one hypothesis, aggregates of A β -peptides could be implicated in the formation of membrane channels that open a gateway to ions. Their uncontrolled exchange between a cell's interior and exterior may alter intracellular ion levels. This could potentially trigger neuronal dysfunctions and may lead to cell death", says Prof. André Fischer, a senior researcher at the DZNE and the UMG.

Pore formation in the spotlight

To test this hypothesis, both artificial and neuronal membranes were investigated in the current study. “Although a definitive proof is still missing, our work supports the assumption that pore formation due to A β -peptides may indeed be involved in Alzheimer’s,” states Ratnesh Lal, a professor of bioengineering at UC San Diego.

Furthermore, the data suggest that although anle138b does not prevent pore formation it induces conformational changes, thereby modifying pore conductivity. This greatly reduces or, in most cases, eliminates ionic flux.



Cross-section of a cell’s membrane (schematic representation): The chemical compound anle138b (orange) seems to close harmful openings (blue) in the membrane of nerve cells. The drug could possibly be used to treat Alzheimer’s. An international collaboration reports on this in the journal *EMBO Molecular Medicine*. (Image: DZNE)

Tests in an animal model

Anle138b was synthesized at the MPI-BPC in the department of Prof. Christian Griesinger in collaboration with Armin Giese from the Ludwig-Maximilians-Universität Munich (LMU). In previous studies, the compound has been shown to prevent misfolding of certain proteins that play a role in neurodegenerative diseases. “Anle138b attaches to protein aggregates, thereby modifying their properties. The drug is able to reach the brain when taken orally. Therefore, it is easy to administer,” Griesinger explains.

In the current study, anle138b was given to mice affected by abnormal brain function, impaired memory, and A β -peptides accumulating in their brains. Similar conditions manifest in Alzheimer’s patients. Treatment with anle138b normalized the rodents’ brain activity and improved their learning ability, irrespective of whether the intervention started before or after the onset of A β deposition. “It came as a big surprise that this positive effect also took place when the disease was well advanced,” says Prof. Martin Korte of the Technische Universität Braunschweig.

Disease-modifying properties

Moreover, the researchers studied the drug’s action on gene expression. For this, they examined the expression levels of neurons of the hippocampus, a brain area involved in memory function. They found that numerous genes were deregulated in the diseased mice. However, anle138b treatment to a large extent reinstated gene expression and thus a healthy balance of proteins. This suggests that the substance not only mitigates symptoms but also affects the disease process and acts disease-modifying.

Effect on Tau proteins

These results are in agreement with earlier findings revealing that anle138b acts on a protein called Tau, a second protein involved in Alzheimer’s. These experiments showed that anle138b eased cognitive deficits in mice affected by Tau aggregation and inhibited Tau proteins from sticking together.

“Care has to be taken when interpreting all these results, because none of the current animal models fully recapitulates the symptoms seen in Alzheimer’s patients,” emphasizes Prof. Gregor Eichele, Director at the MPI-BPC.

“However, anle138b is certainly quite unique, as it interferes with both of the two major hallmarks of Alzheimer’s disease, namely A β -peptides and Tau proteins. I would thus consider it a potential candidate for clinical trials on Alzheimer’s and perhaps other neurodegenerative conditions,” DZNE researcher Fischer adds.

Preparatory work is already in progress: Anle138b is to be developed for market rollout by MODAG, a joint spin-off of the LMU and the MPI-BPC. The researchers hope that anle138b might one day help to stop pathological conditions such as Parkinson’s, Alzheimer’s, and Creutzfeldt Jakob disease.

*Joint press release
of the DZNE, MPI-BPC, UMG, Technische Universität Braunschweig, and CNMPB*

Original publication

Ana Martinez Hernandez et al.: The diphenylpyrazol compound anle138b blocks A β channels and rescues disease phenotypes in a mouse model for amyloid pathology. *EMBO Molecular Medicine*, doi: 10.15252/emmm.201707825 (2017).

Research groups involved in this project

www.dzne.de/en/sites/goettingen/forschergruppen/fischer.html – Website of the research group Epigenetics and Systems Medicine in Neurodegenerative Diseases by Prof. Dr. André Fischer, DZNE, Germany

fischerlab.uni-goettingen.de – Website of Prof. Dr. André Fischer’s laboratory at the Universitätsmedizin Göttingen, Germany

www.mpibpc.mpg.de/griesinger – Website of the Department of NMR-based Structural Biology by Prof. Dr. Christian Griesinger, Max Planck Institute for Biophysical Chemistry, Germany

www.mpibpc.mpg.de/eichele – Website of the Department of Genes and Behaviour by Prof. Dr. Gregor Eichele, Max Planck Institute for Biophysical Chemistry, Germany

<http://www.zoologie.tu-bs.de/index.php/en/cellular-neurobiology/research> – Website of the Department of Cellular Neurobiology by Prof. Dr. Martin Korte at the Technische Universität Braunschweig, Germany

iem.ucsd.edu/people/profiles/ratneshwar-lal.html – Website of Prof. Dr. Ratneshwar Lal at the Institute of Engineering in Medicine at the University of California San Diego, United States

Contact

Dr. Marcus Neizert
DZNE
Media Relations Manager
Phone: +49 228 43302-267
Email: marcus.neizert@dzne.de

Dr. Frederik Köpper
Max Planck Institute for Biophysical Chemistry
Press and Public Relations
Phone: +49 551 201-1310
Email: frederik.koepper@mpibpc.mpg.de

Stefan Weller
University Medical Center Göttingen
Head of Press and Public Relations
Phone: +49 551 39-9959
Email: sweller@med.uni-goettingen.de

Stephan Nachtigall
Technische Universität Braunschweig
Press Officer
Phone: +49 531 391-2160
Email: s.nachtigall@tu-braunschweig.de

Liezel Labios
UC San Diego Jacobs School of Engineering
Public Information Officer
Phone: +1 858 246 1124
Email: llabios@ucsd.edu